Semuloparin
Semuloparin
Semuloparin (pronunciation: /sɛmʊˈlɒpərɪn/) is an anticoagulant medication that was developed for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopedic surgery. It is a type of low molecular weight heparin (LMWH).
Etymology
The name "Semuloparin" is derived from the Latin words "semi", meaning half, and "lupus", meaning wolf. This is in reference to the medication's half-life and its aggressive action against blood clots, similar to a wolf's aggressive nature.
Pharmacology
Semuloparin works by inhibiting Factor Xa, a key enzyme in the coagulation cascade. This prevents the formation of fibrin, the main component of blood clots. It is administered via subcutaneous injection.
Clinical Use
Semuloparin was primarily used in the prevention of VTE in patients undergoing major orthopedic surgery, such as hip or knee replacement. However, it was withdrawn from the market due to safety concerns and lack of efficacy compared to other LMWHs.
Related Terms
- Anticoagulant
- Venous thromboembolism
- Low molecular weight heparin
- Factor Xa
- Coagulation cascade
- Fibrin
External links
- Medical encyclopedia article on Semuloparin
- Wikipedia's article - Semuloparin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski